Cargando…

FLUID study: study protocol for an open-label, single-centre pilot study to investigate the efFect of Lemborexant on sleep management in Japanese sUbjects aged 50 years and older with Insomnia Disorder

INTRODUCTION: Bidirectional associations have been reported between sleep disturbance and both cognitive impairment, including Alzheimer’s disease and amyloid beta-peptide (Aβ) accumulation. These relationships can be explained by the glymphatic system, which acts as a garbage drainage system in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okada, Ippei, Iwamoto, Kunihiro, Miyata, Seiko, Fujimoto, Akihiro, Tanaka, Masaki, Amano, Manabu, Matsuyama, Nao, Taoka, Toshiaki, Naganawa, Shinji, Ozaki, Norio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Mental Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727681/ https://www.ncbi.nlm.nih.gov/pubmed/34836909 http://dx.doi.org/10.1136/bmjopen-2021-054885

Ejemplares similares

Lemborexant for insomnia
Publicado: (2021)

The effect of lemborexant for insomnia disorder
por: Suzuki, Hidenobu, et al.
Publicado: (2021)

Pilot Study of Lemborexant for Insomnia in Cancer Patients with Delirium
por: Terada, Tatsuto, et al.
Publicado: (2022)

Efficacy and safety of lemborexant in midlife women with insomnia disorder
por: Terauchi, Masakazu, et al.
Publicado: (2023)

A Study of Factors Causing Sleep State Misperception in Patients with Depression
por: Kawai, Keita, et al.
Publicado: (2022)

PSUN201 Efficacy and Safety of Lemborexant in Diabetic Patients With Insomnia Disorder
por: Moline, Margaret, et al.
Publicado: (2022)

Efficacy and safety of lemborexant over 12 months in Asian adults with insomnia disorder
por: Dash, Amitabh, et al.
Publicado: (2022)

Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis
por: McElroy, Heather, et al.
Publicado: (2021)

Assessment of morning sleep propensity with lemborexant in adults with insomnia disorder in a randomized, placebo-controlled crossover study
por: Mayleben, David, et al.
Publicado: (2021)

P097 Incidence of abnormal dreams and nightmares with lemborexant in adults with insomnia: results from two Phase 3 studies
por: Roth, T, et al.
Publicado: (2021)

Effects of e-aid cognitive behavioural therapy for insomnia (eCBTI) to prevent the transition from episodic insomnia to persistent insomnia: study protocol for a randomised controlled trial
por: Yang, Yuan, et al.
Publicado: (2019)

‘Mindfulness Living with Insomnia’: an mHealth intervention for individuals with insomnia in China: a study protocol of a randomised controlled trial
por: Pan, Chen, et al.
Publicado: (2022)

Comparison of the effect of lemborexant and other insomnia treatments on driving performance: a systematic review and meta-analysis
por: McElroy, Heather, et al.
Publicado: (2021)

P096 Subjective ratings of medication strength of lemborexant over 6 months in subjects with moderate or severe insomnia
por: Drake, C, et al.
Publicado: (2021)

Design of a treatment pathway for insomnia in prison settings in England: a modified Delphi study
por: Dewa, Lindsay H, et al.
Publicado: (2018)

Effect of small molecule signaling in PepFect14 transfection
por: Gestin, Maxime, et al.
Publicado: (2020)

Open-label placebo for insomnia (OPIN): study protocol for a cohort multiple randomised controlled trial
por: Colagiuri, Ben, et al.
Publicado: (2021)

Effect of discontinuation of lemborexant following long‐term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial
por: Takaesu, Yoshikazu, et al.
Publicado: (2023)

Sleep fragmentation and working memory in healthy adults
por: Okuda, Masato, et al.
Publicado: (2021)

Sleep Treatment Outcome Predictors (STOP) Pilot Study: a protocol for a randomised controlled trial examining predictors of change of insomnia symptoms and associated traits following cognitive–behavioural therapy for insomnia in an unselected sample
por: Denis, Dan, et al.
Publicado: (2017)

Efficacy and safety of electroacupuncture on treating depression-related insomnia: a study protocol for a multicentre randomised controlled trial
por: Yin, Xuan, et al.
Publicado: (2019)

Wisconsin Card Sorting Test scores and clinical and sociodemographic correlates in Schizophrenia: multiple logistic regression analysis
por: Banno, Masahiro, et al.
Publicado: (2012)

Depression, anxiety and insomnia among frontline healthcare workers amid the coronavirus pandemic (COVID-19) in Jordan: a cross-sectional study
por: Oteir, Alaa O, et al.
Publicado: (2022)

Overcoming insomnia: protocol for a large-scale randomised controlled trial of online cognitive behaviour therapy for insomnia compared with online patient education about sleep
por: Kallestad, Håvard, et al.
Publicado: (2018)

Effects of long sleep time and irregular sleep–wake rhythm on cognitive function in older people
por: Okuda, Masato, et al.
Publicado: (2021)

Can Lemborexant for Insomnia Prevent Delirium in High-Risk Patients with Pancreato-Biliary Disease after Endoscopic Procedures under Deep Sedation?
por: Ogura, Takeshi, et al.
Publicado: (2022)

Effects of a hybrid digital cognitive–behavioural therapy for insomnia and emotion regulation in the workplace (SLEEP): study protocol for a randomised waitlist control trial
por: Moukhtarian, Talar Rita, et al.
Publicado: (2022)

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Dayal, Satish, et al.
Publicado: (2021)

Randomised controlled trial on the effect of internet-delivered computerised cognitive–behavioural therapy on patients with insomnia who remain symptomatic following hypnotics: a study protocol
por: Sato, Daisuke, et al.
Publicado: (2018)

The Sleep Condition Indicator: a clinical screening tool to evaluate insomnia disorder
por: Espie, Colin A, et al.
Publicado: (2014)

Pilot evaluation of the Sleep Ninja: a smartphone application for adolescent insomnia symptoms
por: Werner-Seidler, Aliza, et al.
Publicado: (2019)

Digital cognitive–behavioural therapy for insomnia compared with digital patient education about insomnia in individuals referred to secondary mental health services in Norway: protocol for a multicentre randomised controlled trial
por: Kallestad, Håvard, et al.
Publicado: (2021)

Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial
por: Rosenberg, Russell, et al.
Publicado: (2019)

Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder
por: Lalovic, Bojan, et al.
Publicado: (2020)

PepFect14 mediates the delivery of mRNA into human primary keratinocytes and in vivo
por: Periyasamy, Kapilraj, et al.
Publicado: (2023)

Primary care treatment of insomnia: study protocol for a pragmatic, multicentre, randomised controlled trial comparing nurse-delivered sleep restriction therapy to sleep hygiene (the HABIT trial)
por: Kyle, Simon D, et al.
Publicado: (2020)

Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant
por: Landry, Ishani, et al.
Publicado: (2020)

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Landry, Ishani, et al.
Publicado: (2021)

Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2
por: Kärppä, Mikko, et al.
Publicado: (2020)

Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant
por: Khazaie, Habibolah, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_71vps1ke93n57v9iau2ohr1d98